Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tirat Carmel Mental Health Center
With
Technion, Israel Institute of Technology
Ben-Gurion University of the Negev
Beersheva Mental Health Center
Sha'ar Menashe Mental Health Center
HaEmek Medical Center, Israel
The Nazareth Hospital, Israel
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DSM-IV criteria for schizophrenia (American Psychiatric Association 2000)
All clozapine mono-therapy patients (only 300 mg/day) who respond to treatment and achieved symptomatic remission (45, 46) and were stable for at least 3 month will be included
No change in benzodiazepine medications for the trial period.
Legal ability and willingness to sign an informed consent form for participation in the study.
You may not be if
Evidence of serious neurologic or endocrine disorder, for example severe head trauma, seizure disorder, dementia, Cushing's disease, thyroid disorder, mental retardation, alcohol or drug abuse, substance dependence (other than nicotine dependence), or presenting symptoms likely substance- induced, as judged by a study physician.
Unstable medical illness or neurologic illness (seizures, CVA); breast, uterine, or ovarian cancer.
Pregnant women, use of oral contraceptives or other hormonal supplementation such as estrogen. \[Female patients will also have a pregnancy test.\].
Clareo Health | Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients
